Skip to main content
. Author manuscript; available in PMC: 2024 Oct 9.
Published in final edited form as: Cancer Cell. 2023 Sep 28;41(10):1731–1748.e8. doi: 10.1016/j.ccell.2023.09.006

Figure 3. TP53 truncating mutations decrease overall survival of NSCLC patients receiving ICB.

Figure 3.

Overall survival of NSCLC patients carrying TP53 wild-type, TP53 truncating mutations (nonsense and frameshift mutations combined) and TP53 missense mutations after receiving ICB. STK11/KEAP1 WT cases were included in the analysis. Source of the data are as follows.

(A) Samstein et al35, Nature Genetics, 2019. Log-rank test.

(B) AACR Genie, patients treated with pembrolizumab. Log-rank test.

(C) Ravi et al 36, Nature Genetics, 2023.

(D) NSCLC patients from DFCI cohort.